UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2024
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant's name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On May 6, 2024, BioNTech SE (the "Company") provided a development update and reported its financial results for the three months ended March 31, 2024. The interim condensed consolidated financial statements as well as the operating and financial review and prospects of the Company for the three months ended March 31, 2024 are attached hereto as Exhibit 99.1 and shall be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and incorporated by reference herein.
SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BioNTech SE
By: /s/ Jens Holstein
Name: Jens Holstein
Title: Chief Financial Officer
Date: May 6, 2024
EXHIBIT INDEX
Exhibit | Description of Exhibit |
99.1 Quarterly Report for the Three Months Ended March 31, 2024
Exhibit 99.1
BioNTech SE
Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2024
Exhibit 99.1
Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.
Exhibit 99.1
Unaudited Interim Condensed Consolidated Financial Statements
Interim Condensed Consolidated Statements of Profit or Loss | 1 | |
Interim Condensed Consolidated Statements of Comprehensive Income | 2 | |
Interim Condensed Consolidated Statements of Financial Position | 3 | |
Interim Condensed Consolidated Statements of Changes in Stockholders' Equity | 4 | |
Interim Condensed Consolidated Statements of Cash Flows | 5 | |
Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements | 6 | |
1 | Corporate Information | 6 |
2 | Basis of Preparation, Significant Accounting Policies and further Accounting Topics | 6 |
3 | Revenues from Contracts with Customers | 7 |
4 Income and Expenses | 8 | |
5 Income Taxes | 9 | |
6 | Financial Assets and Financial Liabilities | 11 |
7 | Issued Capital and Reserves | 14 |
8 Share-Based Payments | 14 | |
9 | Contingencies | 15 |
10 Related Party Disclosures | 18 | |
11 Events after the Reporting Period | 18 |
Operating and Financial Review and Prospects
Operating Results | 20 |
Liquidity and Capital Resources | 40 |
Risk Factors | 43 |
Unaudited Interim Condensed Consolidated Financial Statements
Interim Condensed Consolidated Statements of Profit or Loss
Three months ended | ||||
March 31, | ||||
2024 | 2023 | |||
(in millions €, except per share data) | Note | (unaudited) | (unaudited) | |
Revenues | 3 | 187.6 | 1,277.0 | |
Cost of sales | 4.1 | (59.1) | (96.0) | |
Research and development expenses | 4.1 | (507.5) | (334.0) | |
Sales and marketing expenses | 4.1 | (15.6) | (12.2) | |
General and administrative expenses | (1) | (117.0) | (111.8) | |
4.1 | ||||
Other operating expenses (1) | 4.2 | (23.9) | (125.7) | |
Other operating income | 4.3 | 28.3 | 57.1 | |
Operating income / (loss) | (507.2) | 654.4 | ||
Finance income | 4.4 | 180.1 | 82.3 | |
Finance expenses | 4.4 | (4.7) | (29.0) | |
Profit / (Loss) before tax | (331.8) | 707.7 | ||
Income taxes | 5 | 16.7 | (205.5) | |
Profit / (Loss) for the period | (315.1) | 502.2 | ||
Earnings / (Loss) per share | ||||
Basic earnings / (loss) for the period per share | (1.31) | 2.07 | ||
Diluted earnings / (loss) for the period per share | (1.31) | 2.05 | ||
- Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (please see Note 4.2 for further details).
The accompanying notes form an integral part of these interim consolidated financial statements.
1
Interim Condensed Consolidated Statements of Comprehensive Income
Three months ended | ||||
March 31, | ||||
2024 | 2023 | |||
(in millions €) | Note | (unaudited) | (unaudited) | |
Profit / (Loss) for the period | (315.1) | 502.2 | ||
Other comprehensive income | ||||
Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax | ||||
Exchange differences on translation of foreign operations | 15.4 | (2.1) | ||
Net gain on cash flow hedges | - | 1.7 | ||
Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent | 15.4 | (0.4) | ||
periods | ||||
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax | ||||
Net gain on equity instruments designated at fair value through other comprehensive income | 6.9 | - | ||
Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods | 6.9 | - | ||
Other comprehensive income / (loss) for the period, net of tax | 22.3 | (0.4) | ||
Comprehensive income / (loss) for the period, net of tax | (292.8) | 501.8 | ||
The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.
2
Interim Condensed Consolidated Statements of Financial Position
March 31, | December 31, | ||
(in millions €) | 2024 | 2023 | |
Assets | Note | (unaudited) | |
Non-current assets | |||
Goodwill | 368.7 | 362.5 | |
Other intangible assets | 821.7 | 804.1 | |
Property, plant and equipment | 802.6 | 757.2 | |
Right-of-use assets | 228.3 | 214.4 | |
Other financial assets | 6 | 1,587.2 | 1,176.1 |
Other non-financial assets | 83.2 | 83.4 | |
Deferred tax assets | 91.0 | 81.3 | |
Total non-current assets | 3,982.7 | 3,479.0 | |
Current assets | |||
Inventories | 345.4 | 357.7 | |
Trade and other receivables | 6 | 1,639.8 | 2,155.7 |
Contract assets | 12.1 | 4.9 | |
Other financial assets | 6 | 6,689.9 | 4,885.3 |
Other non-financial assets | 337.0 | 280.9 | |
Income tax assets | 273.3 | 179.1 | |
Cash and cash equivalents | 8,976.6 | 11,663.7 | |
Total current assets | 18,274.1 | 19,527.3 | |
Total assets | 22,256.8 | 23,006.3 | |
Equity and liabilities | |||
Equity | |||
Share capital | 248.6 | 248.6 | |
Capital reserve | 1,228.9 | 1,229.4 | |
Treasury shares | (10.8) | (10.8) | |
Retained earnings | 19,448.2 | 19,763.3 | |
Other reserves | (946.7) | (984.6) | |
Total equity | 19,968.2 | 20,245.9 | |
Non-current liabilities | |||
Lease liabilities, loans and borrowings | 6 | 205.0 | 191.0 |
Other financial liabilities | 6 | 40.6 | 38.8 |
Provisions | 8.8 | 8.8 | |
Contract liabilities | 379.2 | 398.5 | |
Other non-financial liabilities | 9.6 | 13.1 | |
Deferred tax liabilities | 39.4 | 39.7 | |
Total non-current liabilities | 682.6 | 689.9 | |
Current liabilities | |||
Lease liabilities, loans and borrowings | 6 | 31.3 | 28.1 |
Trade payables and other payables | 6 | 298.8 | 354.0 |
Other financial liabilities | 6 | 152.4 | 415.2 |
Income tax liabilities | 353.2 | 525.5 | |
Provisions | 247.0 | 269.3 | |
Contract liabilities | 361.3 | 353.3 | |
Other non-financial liabilities | 162.0 | 125.1 | |
Total current liabilities | 1,606.0 | 2,070.5 | |
Total liabilities | 2,288.6 | 2,760.4 | |
Total equity and liabilities | 22,256.8 | 23,006.3 | |
The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
BioNTech SE published this content on 06 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2024 16:58:06 UTC.